KANGHUI PHARMACEUTICAL released its performance for the first half of the year, with a net loss attributable to the parent company of 40.2036 million yuan, an increase of 362.01%
I'm PortAI, I can summarize articles.
KANGHUI PHARMACEUTICAL released its semi-annual report for 2025, with operating revenue of 248 million yuan, a year-on-year decrease of 6.83%. The net loss attributable to the parent company was 40.2036 million yuan, a year-on-year increase of 362.01%. The net loss after deducting non-recurring gains and losses was 42.8271 million yuan, a year-on-year increase of 167.89%. The basic loss per share was 0.4 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments